Advertisement
Home Blog Page 3688
Fc gamma receptor 3B (FCGR3B) copy number loss is associated with increased risk of systemic lupus erythematosus and lupus nephritis

FCGR3B Copy Number Loss Ups SLE, Lupus Nephritis Risk

0
Increased risk of systemic lupus erythematosus, lupus nephritis with copy number loss, not gain
For U.S. adults with gastroesophageal reflux disease

Proton Pump Inhibitors Linked to Increased Risk of MI

0
No increased risk seen with H2-blockers
In what researchers are hailing as a medical breakthrough

Birth Reported From Transplanted Childhood Ovarian Tissue

0
Transplant led to functioning ovary and then normal pregnancy

American Diabetes Association, June 5-9

0
The American Diabetes Association's 75th Scientific Sessions The annual meeting of the American Diabetes Association (ADA) was held from June 5 to 9...
Older adults need a protein-rich diet to maintain lower body muscle mass and strength

Different Protein Sources Vary in Effect on Elderly Muscle

0
Both animal and plant sources are important
An analysis of the current state of medical ethics education in the United States has been published in the June issue of Academic Medicine. The article

Report Offers Guidance on Medical Ethics Education

0
Novel approaches to learning encouraged, such as flipped classroom, use of reflective narratives
For residents

Geographic Location Most Important for Residents

0
Lifestyle, adequate call hours and personal time, good financial package also important
One dose of the human papillomavirus vaccine Cervarix could prevent as many cases of cervical cancer as the current two- and three-dose schedules

One Vaccine Dose May Adequately Protect Against HPV

0
Two large international trials suggest single immunization may be as good as two or three
Antibiotic-resistant infections from foodborne germs still cause about 440

CDC: Drug-Resistant Foodborne Bacteria on Rise

0
Rate more than doubled in two years for one strain of Salmonella
U.S. health experts voted on Tuesday to recommend approval of the first of two drugs in a new class of cholesterol medications that reduce low-density lipoprotein cholesterol in patients who don't fare well on statins. The related research was published online April 28 in the Annals of Internal Medicine.

FDA Panel Recommends Approval for PCSK9 Inhibitor

0
Could be used by patients who don't respond to statins